[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Chinese vaccine comparisons", "description": "Chinese and Western vaccines compared\n\nhttps://www.bbc.co.uk/news/world-asia-china-63855508\n\nBig changes, all of a sudden\n\nLive with the virus\n\nVice-premier, Sun Chunlan\n\nChina entering a new situation\n\nVirus ability to cause disease weakening\n\nLifting most severe Covid policies\n\nEnd of quarantine camps\n\nPeople can isolate at home\n\nNo more family separations\n\nClose contacts not taken to camps\n\nStrict ban on blocking fire exits\n\nNo need to show tests for venues\n\nLess rules on internal travel\n\nLateral flow tests to replace PCR tests in most areas\n\nLockdowns continue in smaller more targeted areas\n\nForeign travel soon\n\nCases, 30,000 +\n\nNow\n\nEveryone will be exposed\n\nWill the medical system will be overwhelmed?\n\nNational Health Commission\n\nAll localities, focus on improving the vaccination rate of people aged 60-79, \n\naccelerating the vaccination rate of people aged 80 and above, \n\nand making special arrangements\n\nProf Ivan Hung, Hong Kong University\n\nThe main way for China to exit Covid with the least damage is via vaccination and three doses of vaccination is a must\n\nHopefully before Chinese New Year (January 22) Rabbit\n\nSinopharm\n\nStrategic Advisory Group of Experts on Immunization (SAGE)\n\nhttps://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know\n\nThe vaccine is safe and effective for all individuals aged 18 and above. \n\nIndividuals may choose to delay vaccination for 3 months following the infection.\n\nAn inactivated vaccine with adjuvant\n\n(that is routinely used in many other vaccines)\n\nwith a documented good safety profile, including in pregnant women. \n\nSymptomatic SARS-CoV-2 infection and efficacy against hospitalization 79%\n\nDoes it prevent infection and transmission?\n\nNo substantive data\n\nDoes it work against new variants of SARS-\nCoV-2 virus?\n\nSAGE currently recommends using this vaccine\n\nNot yet been evaluated in the context of circulation of widespread variants of concern.\n\nHow does this vaccine compare to other vaccines already in use?\n\nWe cannot compare the vaccines head-to-head,\n\n(different approaches taken in designing the respective studies)\n\nbut overall, all of the vaccines that have achieved WHO Emergency Use Listing,\n\nare highly effective in preventing severe disease and hospitalization due to COVID-19.\n\nComparison with Western vaccines\n\nPfizer original paper\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2034577\n\nhttps://www.nejm.org/doi/suppl/10.1056/NEJMoa2034577/suppl_file/nejmoa2034577_appendix.pdf\n\nBNT162b2 was 95% effective in preventing Covid-19\n\nLater analysis from \n\nEfficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115787/\n\nAAR, Pfizer, during the trial period,\n\n0.84%\n\nAAR\n\nhttps://patient.info/news-and-features/calculating-absolute-risk-and-relative-risk\n\nAbsolute risk of a disease is your risk of developing the disease over a time period. \n\nFive to six-months update, AAR\n\nBNT162b2  3.7%\n\nmRNA1273 (Moderna-NIH)  4.9%", "link": "https://www.youtube.com/watch?v=MN315cA3Aaw", "date_published": "2022-12-11 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]